Justice Gorsuch authored a unanimous opinion arching back to precedent from the 1800s and upholding the Federal Circuit’s and district court’s determinations that Amgen’s patent claims are invalid for lack of enablement....more
In the April 3, 2023 decision in Ironburg Inventions Ltd. v. Valve Corporation, 21-2296, Doc. 66, the Federal Circuit provides crucial guidance regarding inter partes review (IPR) estoppel under 35 U.S.C. § 315(e)(2). In...more
The oral arguments at the Supreme Court in Amgen v. Sanofi did not make the ultimate decision clear but did clarify many of the likely issues to be addressed....more
In the Hatch-Waxman arena of patent litigation, the crisscross of patent laws and FDA regulations is always in play. In the recent Federal Circuit decision in Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC,...more